Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsGold Coast Health Plan EYLEA Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentGold Coast Health PlanPolicy N/A

    EYLEA, EYLEA HD, and PAVBLU (Aflibercept) Intravitreal Injections

    Customize your policy alerts

    Sign up for all goldcoasthealthplan policy alerts

    Know when goldcoasthealthplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs Part B coverage and prior authorization for physician-administered EYLEA, EYLEA HD, and PAVBLU intravitreal injections for specified retinal conditions in eligible adults and infants.

    Policy Summary
    PayerGold Coast Health Plan
    PolicyEYLEA, EYLEA HD, and PAVBLU (Aflibercept) Intravitreal Injections
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateFeb 12, 2026
    Last ReviewFeb 12, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation confirming the qualifying diagnosis, product and dose, dosing interval, physician-administered intravitreal injection, and required ophthalmologist consultation.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3Covered aflibercept products

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    4
    Adult covered retinal indications
    0.4 mgEYLEA dose for retinopathy of prematurity
    8 mgEYLEA HD intravitreal dose
    6 mo / 12 moCoverage duration

    Covered Indications and Eligibility

    EYLEA/PAVBLU nAMD

    EYLEA or PAVBLU coverage for nAMD requires all of the following:

    All requirements

    • Diagnosis of neovascular (wet) age-related macular degeneration (nAMD).
    • Prescribed by or in consultation with an ophthalmologist.
    • The dose is 2 mg administered by intravitreal injection for each eye being treated.
    • The dosing interval is not more frequent than once every 25 days for each eye being treated.Not more frequently than once every 25 days per eye
    • Administration is by a physician through intravitreal injection in an office or hospital outpatient department.

      Cannot be self-administered.

    EYLEA/PAVBLU macular edema following RVO

    EYLEA or PAVBLU coverage for macular edema following RVO requires all of the following:

    All requirements

    • Diagnosis of macular edema following retinal vein occlusion (RVO).
    • Prescribed by or in consultation with an ophthalmologist.
    • The dose is 2 mg administered by intravitreal injection for each eye being treated.
    • The dosing interval is not more frequent than once every 25 days for each eye being treated.Not more frequently than once every 25 days per eye
    • Administration is by a physician through intravitreal injection in an office or hospital outpatient department.

    EYLEA/PAVBLU DME or DR

    EYLEA or PAVBLU coverage for DME or DR requires all of the following:

    All requirements

    • Diagnosis of diabetic macular edema (DME) or diabetic retinopathy (DR).
    • Prescribed by or in consultation with an ophthalmologist.
    • The dose is 2 mg administered by intravitreal injection for each eye being treated.
    • The dosing interval is not more frequent than once every 25 days for each eye being treated.Not more frequently than once every 25 days per eye
    • Administration is by a physician through intravitreal injection in an office or hospital outpatient department.

    EYLEA retinopathy of prematurity

    EYLEA coverage for retinopathy of prematurity requires all of the following:

    All requirements

    • Diagnosis of retinopathy of prematurity (ROP).
    • Prescribed by or in consultation with a pediatric ophthalmologist.
    • The dose is 0.4 mg administered by intravitreal injection for each eye being treated.0.4 mg per eye
    • The dosing interval is not more frequent than once every 10 days for each eye being treated.Not more frequently than once every 10 days per eye

    EYLEA HD nAMD, RVO, DME, or DR

    EYLEA HD coverage for the applicable adult retinal indication requires all of the following:

    All requirements

    • One qualifying diagnosis

      • Adult diagnosis of neovascular (wet) age-related macular degeneration (nAMD).
      • Adult diagnosis of macular edema following retinal vein occlusion (RVO).
      • Adult diagnosis of diabetic macular edema (DME).
      • Adult diagnosis of diabetic retinopathy (DR).
    • Prescribed by or in consultation with an ophthalmologist.

    Age and population criteria

    Coverage is limited to the following product- and indication-specific populations:

    Eligible populations

    • An adult 18 years or older with nAMD, DME, DR, or macular edema following RVO.Age 18 years or older
    • An infant born before 31 weeks gestation or weighing less than 3.3 pounds with ROP.Born before 31 weeks gestation or weighing < 3.3 pounds

      ROP is covered for the infant population with EYLEA.

    Coverage is excluded when the patient has an ocular or periocular infection, active intraocular inflammation, or hypersensitivity.

    Treatment must be administered by a physician through intravitreal injection in an office or hospital outpatient department (HOPD). Self-administration is not covered.

    Initial Approval Requirements

    Initial therapy

    Initial approval requires all of the following:

    Core authorization requirements

    • Treatment is administered by a physician through intravitreal injection in an office or hospital outpatient department.

      The product cannot be self-administered.

    • One qualifying indication

      • nAMD, macular edema following RVO, DME, or DR for EYLEA or PAVBLU.
      • ROP for EYLEA only.
    • Required specialist involvement

    Continuation and Reauthorization

    Continuation and reauthorization

    Continuation or reauthorization requires all of the following:

    Continuation requirements

    • The requested dose remains within FDA-approved labeling or accepted standards of medical practice.
    • Ongoing treatment for the applicable indication is documented.

      Initial coverage is six months; reauthorization is available for 12 months.

    Billing Codes and Administration Limits

    EYLEA HCPCS CodeHCPCSCovered
    J0178Injection, aflibercept, 1 mg.
    PAVBLU HCPCS CodeHCPCSCovered
    Q5147Injection, aflibercept-ayyh, biosimilar, 1 mg.
    EYLEA HD HCPCS CodeHCPCSCovered
    J0177Injection, aflibercept HD, 1 mg
    Intravitreal Injection ProcedureCPTCovered
    67028Intravitreal injection of a pharmacologic agent (separate procedure)
    Product NDCsNDCCovered
    61755-005-02EYLEA single-dose vial, 10-digit NDC
    61755-0005-02EYLEA single-dose vial, 11-digit NDC
    61755-005-01EYLEA prefilled syringe, 10-digit NDC
    61755-0005-01EYLEA prefilled syringe, 11-digit NDC
    61755-050-01EYLEA HD, 10-digit NDC
    61755-0050-01EYLEA HD, 11-digit NDC
    55513-065-01PAVBLU single-dose vial, 10-digit NDC
    55513-0065-01PAVBLU single-dose vial, 11-digit NDC
    55513-056-01PAVBLU prefilled syringe, 10-digit NDC
    55513-0056-01PAVBLU prefilled syringe, 11-digit NDC
    EYLEA/PAVBLU ROP dosing interval
    ProductEYLEA/PAVBLU for retinopathy of prematurity (ROP)
    Dose0.4 mg by intravitreal injection for each eye being treated
    Maximum frequencyNot more frequently than once every 10 days per eye
    EYLEA/PAVBLU adult dosing interval
    ProductEYLEA/PAVBLU for adult retinal indications
    Dose2 mg by intravitreal injection for each eye being treated

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Obtain product-specific prior authorization

    Prior authorization is required under the Part B clinical guideline for EYLEA, EYLEA HD, and PAVBLU. Approval requires physician-administered intravitreal injection, a qualifying indication, the applicable prescriber specialty or consultation, the product-specific dose, and dosing within the stated limits.

    • Submit the request for the applicable product and retinal indication.
    • Confirm administration by intravitreal injection in an office or hospital outpatient department.
    • Document the required specialist involvement, dose, and dosing interval.
    Documentation Required

    Submit clinical and administration documentation

    Submit documentation of the qualifying diagnosis, product and dose requested, dosing interval, administration by intravitreal injection in an office or hospital outpatient department, and prescription by or consultation with the required ophthalmologist or pediatric ophthalmologist.

    Permitted Administration Settings

    Billing Rule

    Office administration must be physician-performed

    In an office setting, the product must be administered by a physician through intravitreal injection and cannot be self-administered.

    • Use physician administration by intravitreal injection.
    • Do not bill or request coverage for self-administration.
    Billing Rule

    Hospital outpatient administration must be physician-performed

    In a hospital outpatient department, the product may be administered by a physician through intravitreal injection and cannot be self-administered.

    • Document the hospital outpatient administration setting.
    • Use physician administration by intravitreal injection.

    Clinical Background

    Aflibercept is a vascular endothelial growth factor (VEGF) inhibitor administered by intravitreal injection. EYLEA and PAVBLU are used for neovascular age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and macular edema following retinal vein occlusion; EYLEA also has an indication for retinopathy of prematurity. EYLEA HD is an 8 mg formulation used for adult retinal indications with extended dosing intervals.

    Clinical Terms

    Aflibercept
    TermAflibercept
    ClassVascular endothelial growth factor (VEGF) inhibitor
    AdministrationAdministered by intravitreal injection
    nAMD
    AbbreviationnAMD
    MeaningNeovascular (wet) age-related macular degeneration
    Covered productsEYLEA, PAVBLU, and EYLEA HD are indicated for nAMD

    Product Relationship

    Billing Rule

    PAVBLU is covered for specified retinal indications

    PAVBLU (aflibercept-ayyh) is identified as an aflibercept biosimilar to EYLEA (aflibercept) and is covered for neovascular age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and macular edema following retinal vein occlusion. The policy does not state a preferential substitution requirement.

    • PAVBLU HCPCS code: Q5147.
    • Covered indications include nAMD, DME, DR, and macular edema following RVO.
    Policy Summary
    PayerGold Coast Health Plan
    PolicyEYLEA, EYLEA HD, and PAVBLU (Aflibercept) Intravitreal Injections
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateFeb 12, 2026
    Last ReviewFeb 12, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation confirming the qualifying diagnosis, product and dose, dosing interval, physician-administered intravitreal injection, and required ophthalmologist consultation.
    SourceLink
    On This Page
    Covered Indications and EligibilityInitial Approval RequirementsContinuation and ReauthorizationBilling Codes and Administration LimitsAuthorization, Documentation, and Denial RisksPermitted Administration SettingsClinical BackgroundClinical TermsProduct Relationship

    Cannot be self-administered.

    Cannot be self-administered.

    Administration is by a physician through intravitreal injection in an office or hospital outpatient department.

    Cannot be self-administered.

  1. The dose is 8 mg administered by intravitreal injection for each eye being treated.8 mg per eye
  2. For the first three doses, the dosing interval is not more frequent than once every 21 days.Not more frequently than once every 21 days for three doses
  3. After the first three doses, the dosing interval is not more frequent than once every 7 weeks for each eye being treated.Not more frequently than once every 7 weeks per eye
  4. Administration is by a physician through intravitreal injection in an office or hospital outpatient department.

    Cannot be self-administered.

  5. The product is prescribed by or used in consultation with an ophthalmologist for adult retinal indications.
  6. EYLEA for ROP is prescribed by or used in consultation with a pediatric ophthalmologist.
  7. The requested product-specific dose is used: 2 mg for adult EYLEA/PAVBLU indications, 0.4 mg for EYLEA ROP, or 8 mg for EYLEA HD.EYLEA/PAVBLU adult indications: 2 mg; EYLEA ROP: 0.4 mg; EYLEA HD: 8 mg
  8. The dosing interval complies with the applicable product- and indication-specific limit: EYLEA/PAVBLU adult indications not more frequently than once every 25 days per eye; EYLEA ROP not more frequently than once every 10 days per eye; or EYLEA HD not more frequently than once every 21 days for three doses, followed by not more frequently than once every 7 weeks per eye.
  9. Maximum frequencyNot more frequently than once every 25 days per eye
    EYLEA HD initial dosing interval
    ProductEYLEA HD for adult retinal indications
    Dose8 mg by intravitreal injection for each eye being treated
    Initial intervalNot more frequently than once every 21 days for three doses
    EYLEA HD subsequent dosing interval
    ProductEYLEA HD for adult retinal indications
    Dose8 mg by intravitreal injection for each eye being treated
    Subsequent intervalNot more frequently than once every 7 weeks per eye
    • For EYLEA/PAVBLU adult indications, document the 2 mg dose and dosing interval not more frequently than once every 25 days per eye.
    • For EYLEA ROP, document the 0.4 mg dose, pediatric ophthalmologist involvement, and dosing interval not more frequently than once every 10 days per eye.
    • For EYLEA HD, document the 8 mg dose and applicable dosing intervals.
    Documentation Required

    Support reauthorization with ongoing treatment documentation

    For continuation or reauthorization, provide documentation supporting ongoing treatment under FDA-approved labeling or accepted standards of medical practice. The requested dose must remain within those parameters and ongoing indication-specific treatment must be documented.

    • Initial coverage duration: six months.
    • Reauthorization duration: 12 months.
    Denial Risk

    Use physician-administered intravitreal injection

    Coverage may be denied when the drug is self-administered rather than administered by a physician through intravitreal injection in an office or hospital outpatient department.

    • Confirm physician administration for each treatment.
    • Do not use self-administration as the administration method.
    Denial Risk

    Meet all product-specific approval criteria

    Coverage may be denied when the requested diagnosis, prescriber specialty or consultation, dose, or dosing interval does not meet the applicable product-specific approval criteria.

    • EYLEA/PAVBLU adult indications: 2 mg and dosing not more frequently than once every 25 days per eye.
    • EYLEA ROP: 0.4 mg and dosing not more frequently than once every 10 days per eye, with prescription by or consultation with a pediatric ophthalmologist.
    • EYLEA HD: 8 mg, not more frequently than once every 21 days for three doses, followed by not more frequently than once every 7 weeks per eye.
    Denial Risk

    Screen for contraindications before treatment

    Coverage is precluded in the presence of ocular or periocular infection, active intraocular inflammation, or hypersensitivity.

    • Screen for ocular or periocular infection before treatment.
    • Confirm that active intraocular inflammation and hypersensitivity are not present.
    DME
    AbbreviationDME
    MeaningDiabetic macular edema
    Covered productsEYLEA, PAVBLU, and EYLEA HD are indicated for DME
    DR
    AbbreviationDR
    MeaningDiabetic retinopathy
    Covered productsEYLEA, PAVBLU, and EYLEA HD are indicated for DR
    RVO
    AbbreviationRVO
    MeaningRetinal vein occlusion
    Covered indicationMacular edema following RVO
    ROP
    AbbreviationROP
    MeaningRetinopathy of prematurity
    Covered productEYLEA is indicated for treatment of ROP